Key Highlights

● Full-year Revenue guidance rose to $91 billion to $92 billion, the third raise this year.

● Mounjaro and Zepbound Volume growth was more than three times the decline in realized prices.

● Reported EPS guidance fell because of acquired research charges from the AtaiBeckley and Curevo deals.

● Retatrutide beat semaglutide on blood sugar and produced more than twice the weight loss.

Eli Lilly and Company (NYSE:LLY) raised its full-year revenue guidance for a third time this year when it reported third-quarter results on Thursday, October 20-ninth. The Indianapolis drugmaker said sales grew by well over a third compared with the same period a year earlier, powered by sharply higher volumes of its tirzepatide franchise, Mounjaro for type two diabetes and Zepbound for chronic weight management. Realized prices fell by a mid-teens rate, but unit growth was more than three times larger than that decline.

The headline revenue guidance moved up by several billion dollars at the midpoint, yet the company lowered the range for reported earnings per share. The reason is mechanical rather than operational: Lilly booked large acquired in-process Research and Development charges in the quarter after completing deals for AtaiBeckley and Curevo. Management said the underlying raise to earnings guidance was larger than the charge-driven reduction would imply, a distinction that matters when reading the headline numbers.

The report landed alongside a long list of regulatory and pipeline items, from a cardiovascular label for Mounjaro to a head-to-head trial of the experimental triple-agonist retatrutide against semaglutide. Coverage in the days since, including a Tuesday write-up from a widely read financial outlet, has focused on whether the company can keep volumes rising while price per prescription keeps drifting lower.

What did Lilly report for the third quarter?

Lilly said total revenue rose by roughly two-fifths year over year, with volume growth of more than half and a price decline of about one-seventh. That mix tells the central story of the period: more patients and more doses were being supplied, but each unit brought in less money than it did a year earlier. Revenue inside the United States grew by about a third, while revenue outside the country grew faster, at close to half, led mainly by Mounjaro.

Reported Earnings Per Share rose at a mid-teens rate, while the non-GAAP figure, which strips out certain items, rose at a single-digit rate. The gap between the two sits in the acquired research charges, which the company quantified at several dollars per share. A one-time benefit of roughly $900 million, which included milestone payments tied to Jardiance and favorable rebate and discount adjustments, also flattered the quarter, and Lilly noted that no further Jardiance milestones remain.

The press release is the cleanest primary source for these figures, and it is filed with the Securities and Exchange Commission as an exhibit to a current report. Readers comparing outlets should note that some summaries mix reported and non-GAAP measures, so the underlying release is worth opening before relying on any single number.

How big a role did Mounjaro and Zepbound play?

Mounjaro was the largest product in the quarter, with sales above $10 billion and growth of about two-thirds. The split between regions was telling. In the United States Mounjaro grew at a solid but unspectacular pace, while outside the country sales nearly doubled, a reflection of launches in additional markets and broader reimbursement.

Zepbound, the weight-management version of the same molecule, posted sales above $5 billion, up by roughly half. Almost all of that was American, and Lilly said the figure came with lower realized prices. Together the two brands account for the great majority of what the company calls its key products, a category that totaled more than $17 billion in the quarter.

The concentration is worth stating plainly. A company that adds this much revenue from two medicines is exposed to anything that changes their economics, whether that is pricing agreements with governments, competitor launches, or supply. The quarter showed those forces working in different directions at the same time, which is why management framed the story as volume outrunning price.

Why did full-year revenue guidance rise while earnings guidance slipped?

Revenue guidance now sits in a range of 90-$1 billion to $92 billion, up from a prior band in the mid-eighties. The performance Margin guidance, which Lilly uses as an internal measure of operating efficiency, also rose by about two and a half points at the low end. The tax rate guidance edged up by one point.

Earnings guidance moved the other way. The new range for reported earnings per share is 35 to $36, a half-dollar lower than before at both ends. Lilly explained that the underlying improvement at the midpoint was about $4, but that was more than offset by the roughly four-and-a-half-dollar charge for acquired research booked in the quarter.

For readers who track the company, the distinction is practical. Acquired in-process research charges are recognized immediately when a drugmaker acquires an asset that has not yet been approved, so they can produce large swings in reported earnings without changing the revenue base. Whether the market treats such charges as noise or as a real cost of building a pipeline is a matter of preference, and neither view is endorsed here. What is not in dispute is the arithmetic: the charge is large enough to flip the direction of the reported earnings guidance even in a quarter when nearly every operating measure improved.

Which other medicines are growing beyond the two headline brands?

Lilly's release lists a second tier of products that have started to matter. Kisunla, the Alzheimer's antibody, posted sales near $200 million with growth of more than 150%. Jaypirca, for certain blood cancers, and Ebglyss, for atopic dermatitis, each grew by roughly three-fifths to land a little above $200 million. Omvoh, for inflammatory bowel disease, rose by about three-quarters.

Two newer launches also appeared in the table for the first time with meaningful sales. Foundayo, which the company launched this year, recorded sales of close to $200 million, and Inluriyo, a breast cancer medicine, added a smaller amount. The company said that its immunology, oncology and neuroscience key products together roughly doubled from a year earlier.

None of these brands approaches the scale of the tirzepatide franchise, but together they illustrate management's argument that the portfolio is broadening. The numbers are still small against the totals, so the broadening is better read as a direction than as a finished result. Each of these medicines is also at a different stage of its launch curve, which makes year-over-year growth rates look large on a small base.

What regulatory approvals came with the report?

The release cataloged several recent decisions by the Food and Drug Administration. Mounjaro received an indication to reduce cardiovascular exposure in adults with type two diabetes, widening the label beyond blood sugar control. Onswik, a once-weekly basal insulin for adults with type two diabetes, was also approved, as was Inluriyo in combination with Verzenio for a defined group of advanced breast cancer patients.

Jaypirca received an expanded indication covering previously untreated chronic lymphocytic leukemia and small lymphocytic lymphoma, and Olumiant gained approval for adolescents aged 12 and older with severe alopecia areata. Each of these changes extends the population a product can reach, although the pace at which prescriptions follow a label change varies widely by therapeutic area.

Regulatory milestones of this kind rarely move quarterly revenue on their own, but they shape how many prescribers and insurers need to be persuaded. Lilly's own commentary treated the cluster of approvals as evidence of steady execution rather than as a single dramatic event.

What did the head-to-head retatrutide trial show?

Among the pipeline items, the most closely watched was a late-stage head-to-head study in type two diabetes. According to the company, retatrutide produced a larger reduction in the blood sugar marker A-one-C than semaglutide at its two-milligram dose, and it delivered more than twice the weight loss. Retatrutide acts on three hormone receptors rather than the one or two addressed by earlier medicines, which is why the molecule has drawn so much attention.

The company also reported positive late-stage results for Ebglyss in hand and foot atopic dermatitis, and positive mid-stage results for a second tirzepatide-based combination in people with obesity and type two diabetes. Phase three studies for that combination are scheduled to begin in the fourth quarter.

Trial readouts described in a corporate release are not the same as regulatory approval, and full data are typically presented later at scientific meetings and in journals. Until those details are public, outside observers cannot judge safety, discontinuation rates or how the results will translate into labeling.

How are acquisitions shaping the quarter?

The research charge in the quarter came mainly from two completed transactions. AtaiBeckley, which works on treatment-resistant depression and related mental health conditions, closed during the period, and Curevo, a developer of a shingles-related program, was the second. The release also notes a third deal for Merida Biosciences, which focuses on autoimmune and allergic diseases and was described as completed after the quarter ended, though the news list in the same document uses the language of an agreement to acquire.

Acquiring unapproved Assets is a long-standing way for large drugmakers to refill their pipelines, and the accounting treatment explains why a quarter of record sales can still show a lower reported earnings guidance. The deals also signal that Lilly intends to move beyond metabolic disease into psychiatry and immunology.

The company did not attach financial projections to the new assets, which is typical at this stage. Disclosures for early-stage programs usually describe the scientific rationale and the expected timing of the first human studies, not revenue ambitions, and Lilly followed that convention here. Their contribution, if any, would come years later and would depend on trial results that have not been produced yet. For now the main visible effect is on the earnings statement, through the charge, rather than on sales.

Where is Lilly adding Manufacturing capacity?

Supply has been a recurring theme for incretin-based medicines, and the release addressed it directly. Lilly said it broke ground on new American manufacturing sites in Houston, Texas, and Richmond, Virginia, adding to a sequence of announced facilities across the country.

Manufacturing has been one of the practical limits on how fast the category could grow, so each new site is read as a signal about how the company expects Demand to develop. Large-scale pharmaceutical plants take years to design, build and qualify with regulators, so the new sites speak to demand expectations several years out rather than to the current quarter. They also fit a broader pattern in which drugmakers highlight domestic production amid Tariff discussions and pricing negotiations with the federal government.

The release did not detail the Capital cost of the two new sites in the section reviewed here. Readers wanting that figure should look at the company's filings and Capital Expenditure disclosures rather than at summaries.

How does the quarter fit the wider sector picture?

The result is part of a busy reporting season for Healthcare Stocks, in which large drugmakers have been reporting how pricing agreements, tariffs and new launches are feeding through to results. Lilly's pattern, with volume rising quickly and price falling, differs from companies facing Patent expiries on older blockbusters, and the contrast is visible in the way different company updates have been received.

Lilly is a heavyweight constituent of the S&P 500, which means its quarterly swings are also followed as a gauge of how much weight a single product class now carries in large-cap healthcare. A Tuesday article from a financial outlet put the quarter in the context of a company whose growth rate far exceeds that of a large peer reporting in the same week.

The comparison is useful context but not a projection. Different companies sit at different points in their product cycles, and a high growth rate in one quarter does not determine the rate in the next.

What is the pricing backdrop?

The most important outside variable for Lilly is the arrangement it reached with the federal government on pricing and access for its obesity and diabetes medicines. The company's own commentary referred to a first full quarter of Medicare coverage for certain uses, and one outside write-up framed it as a question of whether volume could continue to outrun price reductions.

Realized price is influenced by rebates, discounts, direct-to-consumer channels and the mix between insured and cash-paying patients. A decline of about one-seventh in a quarter is large by pharmaceutical standards, but Lilly said it was offset many times over by volume.

How far the decline can go, and whether volume can keep pace, are the two open questions in the story. The company did not offer a single-sentence answer, and its guidance simply reflects management's current view of both.

What should readers watch next for Eli Lilly?

The next dated items are the full presentation of the retatrutide data, the start of phase three studies for the second combination molecule, and the close of the Merida Biosciences transaction. The company's fourth-quarter report, normally released in the first part of the next calendar year, will show how close the year lands to the new guidance range.

Other signposts include the rate of launch uptake for Foundayo, whether Kisunla continues to grow at its present pace, and any change to the federal pricing arrangement. Supply updates and the progress of the new factories will matter for the longer run.

The primary sources are the company release and its exhibit filed with the securities regulator, and both are linked in the references.